Gilead May Have Better Takeover Targets Than Tesaro

 
• By Kevin Grogan

Gilead has once more been mentioned as a prospective acquirer of Tesaro, but analysts at Datamonitor Healthcare's PharmaVitae believe that CAR-T and NASH are the areas where the company is more likely to seek buys that reduce its reliance on hepatitis C and HIV therapies.

Fisherman
Gilead to cast its net for assets • Source: Shutterstock

More from Deals

More from Business